VRC01 gp120 complex: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
The crystal structure of VRC01 and VRC01-like antibodies are studied to define with characteristics are important in neutralizing HIV-1. (cite!) | The crystal structure of VRC01 and VRC01-like antibodies are studied to define with characteristics are important in neutralizing HIV-1. (cite!) | ||
<Structure load='3NGB' size='500' frame='true' align='right' caption='Trimeric gp120 in complex with VRC01 antibodies' scene='Insert optional scene name here' /> | <Structure load='3NGB' size='500' frame='true' align='right' caption='Trimeric gp120 in complex with VRC01 antibodies' scene='Insert optional scene name here' /> | ||
==Introduction== | ==Introduction== | ||
HIV-1 has a high level of antigenic and genetic diversity. HIV-1 has also evolved mechanisms to evade the humoral immune response. These aspects of HIV-1 have made it difficult to develop a vaccine. After several years of infection, 10 to 25% of HIV-1 infected individuals develop neutralizing antibodies. Some antibodies target the transmembrane gp41 molecules of the HIV-1 viral spike, however most target the surface protein gp120. (Wu) VRC01 and VRC01-like antibodies bind to gp120 and are able to neutralize about 90% of HIV-1 isolates. Structural analysis has shown which characteristics of antibodies are essential to its binding with gp120. (Kwong) Discovery of the structure of these antibodies can help develop an effective HIV-1 vaccine. | HIV-1 has a high level of antigenic and genetic diversity. HIV-1 has also evolved mechanisms to evade the humoral immune response. These aspects of HIV-1 have made it difficult to develop a vaccine. After several years of infection, 10 to 25% of HIV-1 infected individuals develop neutralizing antibodies. Some antibodies target the transmembrane gp41 molecules of the HIV-1 viral spike, however most target the surface protein gp120. (Wu) VRC01 and VRC01-like antibodies bind to gp120 and are able to neutralize about 90% of HIV-1 isolates. Structural analysis has shown which characteristics of antibodies are essential to its binding with gp120. (Kwong) Discovery of the structure of these antibodies can help develop an effective HIV-1 vaccine. | ||
==HIV-1 Neutralization== | ==HIV-1 Neutralization== | ||
